(Source: Argos Therapeutics Inc) DURHAM, N.C., Nov. 5, 2015 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) ('Argos'), an immuno-oncology company focused on the development and commercialization of fully individualized immunotherapies based on the Arcelis® technology platform, today announced the company will present at the 3rd International mRNA Health Conference being held at the Hilton Berlin in Berlin, GermanyNovember 11-12, 2015. Irina Tcherepanova, Ph.D., Argos's senior director of R&D, will present an update on RNA optimization for ectopic protein expression and increased potency of a cell-based immunotherapy. The presentation is scheduled for 11:40am CET on Thursday,...
↧